📋 Tender Overview
Neuroclues: The Clinical Must-Have For Neurologists: Clinical Validation, Industrialization, And Go-To-Market.
P3Lab Developed Neuroclues, A First-Of-A-Kind Portable, Fast And Easy To Use Eye Tracking Medical Device That Brings Clinically Validated Eye Movement Biomarkers For Movement Disorders (Mds) Into The Clinical Routine Of Neurologists. Neuroclues Will Enable Neurologists To Establish Their Md Diagnosis Faster (From Months To Days) Earlier And More Reliably, And With Diagnostic Grade Accuracy. This Will Enable Neurologists To Start Patient Care Earlier. This Project Aims At Validating And Demonstrating (I) The Usability Of Neuroclues In The Clinical Routine With Early Adopter Kol Neurologists And (Ii) Assess Its Clinical Value In Ongoing And (Iii) In Own Sponsored Clinical Investigation Studies (Eu And Us). This Is Needed To Convince The Broad Majority Of Neurologist Of Neuroclues’ Clinical Value. The Successful Demonstration And Accompanied Development Of Our Go-To-Market Strategy Will Enable P3Lab To Become Investor Ready By 2024 And Profitable By 2027, With €70M Arr Targeted By 2030.
Funded Under
The European Innovation Council (Eic)
Total Cost
€ 5 557 786,50
Eu Contribution
€ 2 500 000,00
Coordinated By
P3 Lab
Belgium
Start Date
1 February 2023
End Date
31 January 2027
Objective
P3Lab developed NeuroClues, a first-of-a-kind portable, fast and easy to use eye tracking medical device that brings clinically validated eye movement biomarkers for movement disorders (MDs) into the clinical routine of neurologists. NeuroClues will enable neurologists to establish their MD diagnosis faster (from months to days) earlier and more reliably, and with diagnostic grade accuracy. This will enable neurologists to start patient care earlier. This project aims at validating and demonstrating (I) the usability of NeuroClues in the clinical routine with early adopter KOL neurologists and (II) assess its clinical value in ongoing and (III) in own sponsored clinical investigation studies (EU and US). This is needed to convince the broad majority of neurologist of NeuroClues’ clinical value. The successful demonstration and accompanied development of our go-to-market strategy will enable P3Lab to become investor r
